Hodgkin Lymphoma
Conference Coverage
Steep cost of surviving childhood HL: Epigenetic aging
New research found accelerated epigenetic aging in most adults who survived pediatric Hodgkin lymphoma.
Conference Coverage
ASH 2022: New clinical data challenge long-held assumptions
Fresh research to be unveiled at the 2022 American Society of Hematology conference seems to overturn conventional wisdom across a range of issues...
Feature
Drug shortages plague hematology, but preparedness helps
The plight of desperate patients is getting attention – and some remedies.
Feature
Woman who faked cancer gets 5 years in prison
Feature
Third-generation Black woman physician makes cancer research history
African American surgeon helped found ASCO and collaborated with her father to achieve lasting breakthroughs in chemotherapy.
Feature
Ex–hospital porter a neglected giant of cancer research
An Indian immigrant who once emptied bedpans in a Boston hospital went on to become the “father of chemotherapy.”
From the Journals
‘Unprecedented crisis’: Hodgkin drug shortage persists
Supply chain problems have triggered shortages of a drug to treat Hodgkin lymphoma, igniting a search for substitutes.
Feature
When CPI fails, HL patients should get timely allo-HCT
New data suggest that physicians should refer Hodgkin lymphoma patients for allogeneic HCT without delay when PD-1 treatments fail.
Feature
Survivor’s story foreshadows one of oncology’s greatest successes
In 1992, a young New Yorker was among the first Hodgkin lymphoma patients to undergo a successful bone marrow transplant. Three decades later,...
Feature
Repurposed drug could revolutionize stem cell transplantation
Abatacept to prevent for acute graft-versus-host disease is a game changer for patients receiving hematopoietic stem cell transplants who lack...
From the Journals
Hodgkin-directed therapy may benefit patients with rare CLL subtype
Patients diagnosed with an uncommon subtype of chronic lymphocytic lymphoma show improved outcomes from Hodgkin-directed treatments.